Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P BCMACD19 ALLO1

Next Previous
Drug Profile

P BCMACD19 ALLO1

Alternative Names: BCMA/CD19 dual-target CAR-T cell immunotherapy - Poseida Therapeutics; BCMA/CD19 dual-targeting CAR-T therapy - Poseida Therapeutics; Dual CAR-BCMA-19- Poseida Therapeutics; P-BCMACD19-ALLO1

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Multiple myeloma

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
  • 07 Nov 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 03 Aug 2022 Poseida Therapeutics enters into a collaboration and license agreement with Roche to develop P BCMACD19 ALLO1

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top